

Brain Tumor Therapeutics: Global Markets to 2023

<https://marketpublishers.com/r/BD3993AB2B9EN.html>

Date: December 2018

Pages: 161

Price: US\$ 1,375.00 (Single User License)

ID: BD3993AB2B9EN

Abstracts

Report Scope:

This report provides an overview of the current and future global market potential for brain tumor therapeutics. It provides a detailed analysis and information about conventional treatment options, ongoing market trends and the future direction of the market with respect to brain tumor therapy.

Inclusions

The report covers a detailed background of the disease state, along with epidemiological and demographic data, market segmentation by therapy (chemotherapy and targeted therapy), age group of patients (adult and pediatric brain tumors), end users (hospitals, cancer research institutes and medical universities) and a detailed regional market analysis including North America, Europe, Asia-Pacific and the rest of the world.

The report provides information on newer treatment opportunities and cutting-edge research on therapeutics for brain tumors. It covers various types of treatment used in the field of neuro-oncology: surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy.

A detailed analysis of agents used in the market for chemotherapy, immunotherapy and targeted therapy, as well as a pipeline analysis of newer molecules and therapeutics is covered in the report.

A comprehensive analysis of market dynamics in the industry and current market trends are described in the report, along with the competitive landscape and discussion about key market players in the field of brain tumor therapeutics,

where market strategies of these players are studied and described. The report includes a patent analysis of brain tumor therapeutics.

The report concludes with company profiles of key players in the development and commercialization of brain tumor therapeutics.

A separate chapter on emerging trends and breakthrough technologies in the field of neuro-oncology has been included in this report.

Exclusions

Excluded from this report are the market size for equipment used in radiotherapy, surgical equipment and supplies and market size for drugs used for the symptomatic management of cancer (anti-epileptics, anti-emetics and hormonal medications). This report also excludes market size for immunotherapy. This is not a proven treatment for brain tumors and is currently being developed in research and clinical trials.

Market values are provided for 2017 as base year, 2018 and forecast through 2023. Estimated values are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

20 data tables and 40 additional tables

Comprehensive overview of the global market for brain tumor therapeutics within the pharmaceutical industry

Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023

Country specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa

Impact analysis of major drivers and restraints, and regional dynamics of the global brain tumor therapeutics markets and current trends within the industry

Company profiles of prominent players in the market, including Bristol-Myers

Squibb Co., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and
Novartis International AG

Contents

CHAPTER 1 INTRODUCTION

Scope of Report
Study Goals and Objectives
Reasons for Doing This Study
Information Sources and Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

Key Findings

CHAPTER 3 DISEASE BACKGROUND AND OVERVIEW

Introduction
What is Cancer?
Cancer Drivers
Cancer Staging
Disease Background
Brain Tumor Statistics
Human Brain Function
Causes of Tumor Development
Mechanism of Tumorigenesis
Types and Classification of Brain Tumors
Diagnosis of Brain Tumors
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Spectroscopy (MRS)
Tissue Sampling/Biopsy/Surgical Removal of Tumor
Computed Tomography (CT)
Positron Emission Tomography (PET) or PET-CT Scan
Cerebral Arteriogram
Lumbar Puncture or Spinal Tap
Myelogram
Molecular Testing

Neurological, Vision and Hearing Tests
Neurocognitive Assessment
Electroencephalography (EEG)
Evoked Potentials
Recurrence of Brain Tumors and Management
Brain Tumor Metastases and Management
Cognitive Challenges
Pain Management
Treatment Modalities
Surgery
Neurosurgery
Emerging Treatments in Neurosurgery
Radiotherapy
New and Emerging Treatments in Neuro-radiotherapy
Chemotherapy
Targeted Therapy
Immunotherapy

CHAPTER 4 MARKET DYNAMICS

Introduction
Market Drivers
Increasing Global Incidence of Brain Cancer
Early Cancer Detection
Research Initiatives
R&D Collaborations
Increase in Oncology Spending
Accelerated Approvals for Drugs Used in Rare Diseases
Market Restraints
Lack of Effective Treatment Options for Brain Tumors
High Cost
Low Screening
Current Market Trends
Immunotherapy
Combination Therapy
MRI-Guided Laser Surgery
Palliative Therapy
3D RADIATION THERAPY
Precision Medicine and Companion Diagnostics

Polymer Wafer Implants
Tumor Treating Fields (TTF)

CHAPTER 5 MARKET BREAKDOWN BY THERAPY

Introduction
Chemotherapy
Overview
Principle of Chemotherapy
BBB and Chemotherapy
Chemotherapeutic Agents
Side Effects of Chemotherapy
New Developments
Market Overview
Market Size and Forecast
Targeted Therapy
Introduction
Precision Medicine in Cancer
Types and Methods of Targeted Therapy
Drug Delivery Systems for Targeted Therapeutics
FDA-Approved Targeted Therapeutics
New Developments
Market Overview
Market Size and Forecast
Immunotherapy
Introduction
Immunotherapeutic Agents
New Developments
Market Overview

CHAPTER 6 MARKET BREAKDOWN BY PATIENT AGE

Introduction
Overview
Treatment Options
Market Overview
Market Size and Forecast

CHAPTER 7 MARKET BREAKDOWN BY END USER

CHAPTER 8 MARKET BREAKDOWN BY REGION

Introduction
North America
Europe
Asia-Pacific
Rest of the World

CHAPTER 9 EMERGING TECHNOLOGIES AND FUTURE TRENDS

Introduction
Cancer Vaccines
Nanomedicine
Stem Cell Therapy
Photodynamic Therapy
Focused Ultrasound Therapy
Radiomics and Pathomics
CRISPR
Artificial Intelligence
Advancements in Genomics and Personalized Medicine

CHAPTER 10 CLINICAL RESEARCH IN BRAIN TUMOR THERAPEUTICS

Introduction
The Drug Development Process
Drug Discovery
Early Formulation Studies
Pre-Clinical Safety Studies
Clinical Trials
Regulatory Review
Post-Marketing Surveillance
Research Initiatives
Defeat GBM Research Collaborative
Cancer Moonshot
End Brain Cancer Initiative
Brain Cancer Translational Research Initiative
Pediatric Brain Tumor Initiative
GLIOTRAIN

GBM Agile
Clinical Trials and Experimental Treatments

CHAPTER 11 PATENT REVIEW

Introduction
Significant Patents

CHAPTER 12 COMPETITIVE LANDSCAPE AND MARKET STRATEGIES

Introduction
Major Players and Market Share Analysis
Market Strategies Employed, by Major Players
Research and Development
Patent Exclusivity
Mergers and Acquisitions (M&A)
New Developments
Porter's Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Threat from New Entrants
Threat from Substitutes
Market Competition

CHAPTER 13 REGULATORY AND REIMBURSEMENT LANDSCAPE

Introduction
Drug Development Regulations
U.S.
Canada
Mexico
Europe
Asia Pacific
ROW
Reimbursement Landscape

CHAPTER 14 COMPANY PROFILES

ASTRA ZENECA PLC

Business Overview

BRISTOL-MYERS SQUIBB CO.

Business Overview

Financial Information

Products and Services

Development and Strategies

CURTANA PHARMACEUTICALS, INC.

Business Overview

DEL MAR PHARMACEUTICALS, INC.

Business Overview

EISAI CO. LTD.

Business Overview

EMCURE PHARMA

Business Overview

F. HOFFMANN-LA ROCHE LTD.

Business Overview

Financial Information

Products and Services

Development and Strategies

Business Highlights

FRESENIUS KABI ONCOLOGY LTD.

Business Overview

IMMUNOCELLULAR THERAPEUTICS LTD.

Business Overview

ITEOS THERAPEUTICS

Business Overview

KAZIA THERAPEUTICS LTD.

Business Overview

MERCK & CO., INC.

Business Overview

Financial Information

Products and Services

Development and Strategies

Business Highlights

NAVINTA LLC

Business Overview

NEXTSOURCE BIOTECHNOLOGY LLC

Business Overview

Products and Services

Development and Strategies

Business Highlights

NORTHWEST BIOTHERAPEUTICS, INC.

Business Overview

NOVARTIS INTERNATIONAL AG

Business Overview

Financial Information

Products and Services

Development and Strategies

Business Highlights

TOCAGEN, INC.

Business Overview

UNITED THERAPEUTICS CORP.

Business Overview

CHAPTER 15 APPENDIX: ACRONYMS

List Of Tables

LIST OF TABLES

Summary Table: Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2023

Table 1: WHO Grading of Brain Tumors

Table 2: WHO Grading of Select Brain Tumors

Table 3: Survival Rates for Common Adult Brain and Spinal Cord Tumors, 2017

Table 4: Brain Structures and Functions

Table 5: WHO Classification of Brain Tumors, 2016

Table 6: Karnofsky Performance Scale

Table 7: Specific Types of Brain Tumor Metastasis

Table 8: Parts of the Brain Related to Major Cognitive Functions

Table 9: Timeline of Significant Developments in Radiotherapy, 1898-2006

Table 10: Rare/Orphan Drug Criteria: Selected Regulatory Organizations

Table 11: Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2023

Table 12: FDA-Approved Drugs Used in Brain Tumor Chemotherapy

Table 13: Dosage and Administration of Temozolomide for Brain Tumors

Table 14: Current Brain Tumor Clinical Trials: Temozolomide

Table 15: Current Brain Tumor Clinical Trials involving Lomustine

Table 16: Current Brain Tumor Clinical Trials involving Carmustine

Table 17: PCV Regimen: Brain Tumor Chemotherapy

Table 18: Global Market for Brain Tumor Chemotherapy, by Region, Through 2023

Table 19: FDA Approved Targeted Therapeutic Agents for Brain Tumors

Table 20: Monoclonal Antibodies

Table 21: Small Molecule Monoclonal Antibodies

Table 22: Current Brain Tumor Clinical Trials involving Bevacizumab

Table 23: Current Brain Tumor Clinical Trials involving Everolimus

Table 24: Global Market for Brain Tumor Targeted Therapy, by Region, Through 2023

Table 25: Current Brain Tumor Clinical Trials: Immunotherapy

Table 26: Global Market for Brain Tumor Therapeutics, by Patient Age, Through 2023

Table 27: Hereditary Factors: Pediatric Brain Tumors

Table 28: Global Market for Adult Brain Tumor Therapeutics, by Region, Through 2023

Table 29: Global Market for Pediatric Brain Tumor Therapeutics, by Region, Through 2023

Table 30: Global Market for Brain Tumor Therapeutics Market, by End User, Through 2023

Table 31: Global Market for Brain Tumor Therapeutics in Hospitals, by Region, Through

2023

Table 32: Global Market for Brain Tumor Therapeutics in Research Institutes, by Region, Through 2023

Table 33: Global Market for Brain Tumor Therapeutics in Universities, by Region, Through 2023

Table 34: Global Market for Brain Tumor Therapeutics , by Region, Through 2023

Table 35: North American Market for Brain Tumor Therapeutics, by Country, Through 2023

Table 36: European Market for Brain Tumor Therapeutics, by Country, Through 2023

Table 37: Asia-Pacific Market for Brain Tumor Therapeutics, by Country, Through 2023

Table 38: Drug Development

Table 39: Selected Current Phase I Brain Tumor Clinical Trials

Table 40: Selected Current Phase II Brain Tumor Clinical Trials

Table 41: Selected Current Phase III Brain Tumor Clinical Trials

Table 42: Patent Review of Novel Compounds and Drug Delivery in Brain Tumors, February 2017 to August 2018

Table 43: Patent Review of Therapeutic Agents for Brain Tumors, January 2017 to August 2018

Table 44: Patent Review of Combination Therapies in Brain Tumors, September 2017 to September 2018

Table 45: Patent Review of Immunotherapies for Brain Tumors, December 2016 to July 2018

Table 46: Patent Review of Diagnosis and Biomarkers in Brain Tumors, January 2017 to September 2018

Table 47: Ongoing Clinical Trials and Product Pipeline Involving Major Players in Brain Tumor Therapeutics

Table 48: Current Orphan Drug Designations for Brain Tumors

Table 49: Bristol-Myers Squibb: Revenue 2016 and 2017

Table 50: Bristol-Myers Squibb: Brain Tumor Pharmaceuticals

Table 51: Opdivo Approvals, 2017

Table 52: F. Hoffmann-La Roche: Revenue 2016 and 2017

Table 53: F. Hoffmann-La Roche: Brain Tumor Pharmaceutical Drugs

Table 54: Merck & Co., Inc.: Revenue 2016 and 2017

Table 55: Merck & Co., Inc.: Brain Tumor Pharmaceutical Drugs

Table 56: NextSource Biotechnology LLC: Brain Tumor Therapeutics

Table 57: Novartis: Revenue 2016 and 2017

Table 58: Novartis: Brain Tumor Pharmaceuticals

Table 59: Important Acronyms Related to Brain Tumor Therapeutics Used in This Report

List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Brain Tumor Therapeutics, by Therapy Type, 2017-2023

Figure 1: Percentage Share of Global Cancer Incidence, by Type, 2018

Figure 2: Percentage Share of Global Cancer Incidence, by Region, 2018

Figure 3: Hallmarks of Cancer

Figure 4: Five Year Relative Survival at Diagnosis, by Stage, 2014-2018

Figure 5: Goals of Surgical Treatment for Brain Tumors

Figure 6: Global Expenditures on Oncology Drugs, by Country/Region, 2013-2017

Figure 7: Projected Global Expenditures on Oncology Drugs, by Country/Region, 2020

Figure 8: Global Market for Brain Tumor Therapeutics, by Therapy Type, 2017-2023

Figure 9: Global Market for Brain Tumor Chemotherapy, by Region, 2017-2023

Figure 10: Targeted Therapy Types

Figure 11: Global Market for Brain Tumor Targeted Therapy, by Region, 2017-2023

Figure 12: Global Market for Brain Tumor Therapeutics, by Patient Age, 2017-2023

Figure 13: Percentage Share of Common Adult Brain Tumor Incidence, by Type, 2017

Figure 14: Percentage Share of Common Pediatric Brain Tumor Incidence, 2017

Figure 15: Differences: Adult and Pediatric Brain Tumors

Figure 16: Etiology: Pediatric Brain Tumors

Figure 17: Global Market for Adult Brain Tumor Therapeutics, by Region, 2017-2023

Figure 18: Global Market for Pediatric Brain Tumor Therapeutics, by Region, 2017-2023

Figure 19: Global Market for Brain Tumor Therapeutics in Hospitals, by Region, 2017-2023

Figure 20: Global Market for Brain Tumor Therapeutics in Research Institutes, by Region, 2017-2023

Figure 21: Global Market for Brain Tumor Therapeutics in Universities, by Region, 2017-2023

Figure 22: Global Incidence of Brain Tumors, 2018-2040

Figure 23: Global Market for Brain Tumor Therapeutics Market, by Region, 2017-2023

Figure 24: North American Incidence of Brain Tumors, 2018-2040

Figure 25: North American Market for Brain Tumor Therapeutics, 2017-2023

Figure 26: North American Market for Brain Tumor Therapeutics, by Country, 2017-2023

Figure 27: European Incidence of Brain Tumors, 2018-2040

Figure 28: European Market for Brain Tumor Therapeutics, 2017-2023

Figure 29: European Market for Brain Tumor Therapeutics, by Country, 2017-2023

- Figure 30: Asia-Pacific Incidence of Brain Tumors, 2018-2040
- Figure 31: Asia-Pacific Market for Brain Tumor Therapeutics, 2017-2023
- Figure 32: Asia-Pacific Market for Brain Tumor Therapeutics, by Country, 2017-2023
- Figure 33: ROW Market for Brain Tumor Therapeutics, 2017-2023
- Figure 34: Pharmaceutical Drug Development
- Figure 35: Current Clinical Trials, by Phase, 2018
- Figure 36: Major Market Players Share in Brain Tumor Therapeutics Market, 2017
- Figure 37: NIH Funding for Brain Cancer R&D, 2016-2018
- Figure 38: R&D Expenditure of Top 3 Players in Brain Tumor Therapeutics, 2017
- Figure 39: Bargaining Power of Buyers in the Brain Tumor Therapeutics Industry
- Figure 40: Bargaining Power of Suppliers in the Brain Tumor Therapeutics Industry
- Figure 41: Threat from New Entrants in the Brain Tumor Therapeutics Industry
- Figure 42: Threat from Substitutes in the Brain Tumor Therapeutics Industry
- Figure 43: Market Competition in the Brain Tumor Therapeutics Industry
- Figure 44: Pharmaceutical Regulatory Pathways in the U.S and Europe
- Figure 45: Bristol-Myers Squibb: Net Sales, by Region/Country, 2017
- Figure 46: Bristol-Myers Squibb: R&D Expenditure, 2016 and 2017
- Figure 47: Roche Top 5 Pharmaceutical Drugs, by Sales Revenue, 2017
- Figure 48: Avastin: Sales Revenue, 2016 and 2017
- Figure 49: F. Hofmann-La Roche: Revenue Share, by Business Segment, 2017
- Figure 50: F. Hofmann-La Roche: Revenue, by Region, 2015-2017
- Figure 51: Roche Product Pipeline, by Disease Area, 2017
- Figure 52: Novartis: Net Sales, by Division, 2017
- Figure 53: Novartis: Net Sales, by Region, 2017

I would like to order

Product name: Brain Tumor Therapeutics: Global Markets to 2023

Product link: <https://marketpublishers.com/r/BD3993AB2B9EN.html>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BD3993AB2B9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970